SCHEMBL13627959

SCHEMBL13627959

O=C1/C(=N\O)c2ccccc2N1Cc1cccc(Oc2ccccc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
MAPT P10636 2/20 0.50
LRRK2 Q5S007 1/20 0.50
PKM P14618 1/20 0.50
TSHR P16473 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HSD17B10 Q99714 1/20 0.50
ALDH3A1 P30838 2/20 0.47
ALDH2 P05091 1/20 0.47
CHRM1 P11229 1/20 0.47
CES1 P23141 1/20 0.47
CA2 P00918 2/20 0.45
LMNA P02545 2/20 0.45
POLB P06746 1/20 0.45
CA12 O43570 1/20 0.45
CA9 Q16790 1/20 0.45
CHRM5 P08912 1/20 0.44
PRKAG1 P54619 2/20 0.43
PRKAA2 P54646 2/20 0.43
PRKAB1 Q9Y478 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627975 0.88 TRPA1 (0.50) ALDH1A1ALDH3A1CA2CA12CA9
SCHEMBL13627965 0.88 ALDH1A1 (0.55) ALDH1A1ALDH3A1ALDH2CA2CA12
SCHEMBL7611051 0.85 ALDH1A1 (0.66) ALDH1A1MAPTLRRK2PKMTSHR
SCHEMBL7611054 0.85 ALDH1A1 (0.66) ALDH1A1MAPTLRRK2PKMTSHR
SCHEMBL13627885 0.83 ALDH1A1 (0.54) ALDH1A1MAPTLRRK2PKMTSHR
SCHEMBL13627897 0.81 UBE2N (0.63) ALDH1A1MAPTLRRK2PKMTSHR
SCHEMBL13627896 0.81 ALDH1A1 (0.53) ALDH1A1MAPTLRRK2PKMTSHR
SCHEMBL13627958 0.81 ALDH1A1 (0.52) ALDH1A1MAPTLRRK2PKMTSHR
SCHEMBL13627989 0.80 ALDH1A1 (0.40) ALDH1A1MAPTLMNACHRM5HPGD
SCHEMBL15923547 0.79 KMT2A (0.60) ALDH1A1MAPTNPSR1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
EP-1175399-B1 INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) VERTEX PHARMA (US) 2009-03-11 EP disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 ALDH1A1 4310/4885MAPT 1666/4885LRRK2 361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.